Porustobart

普鲁苏拜单抗

Report date: 2026/02/26 20:00:22

Base Information

Drug NamePorustobart
Drug Alias NameHBM-4003HCAb 4003-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaHong KongMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHarbour Biomed
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHarbour BioMed (Suzhou) Co LtdSolstice OncologyHarbour Biomed
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A